Frequently Asked Questions
The market is segmented based on Segmentation, By Classification (Functional NET and Non-Functional NET), Site (Lung, Pancreas, Gastrointestinal Tract (GI), and Appendicular), Grade (Grade 1, Grade 2, and Grade 3), Type (Diagnosis and Treatment), Product (Somatostatin Analogs, Targeted Therapy, and Chemotherapy), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other) - Industry Trends and Forecast to 2032
.
The Global Neuroendocrine Tumors Market size was valued at USD 3.56 USD Billion in 2024.
The Global Neuroendocrine Tumors Market is projected to grow at a CAGR of 1.04% during the forecast period of 2025 to 2032.
The major players operating in the market include F. Hoffmann-La Roche Ltd , Bristol Myers Squibb , Viatris Inc. , Thermo Fisher Scientific Inc. , Novartis AG , Regeneron PharmaceuticalsInc. , Sun Pharmaceutical Industries Ltd. , Teva Pharmaceutical Industries Ltd. , Eli Lilly and Company , Lupin , Exact Sciences Corporation , Pfizer Inc. , Ipsen Pharma , Advanced Accelerator Applications , BioSynthema Inc. , Bionano GenomicsInc.U.S.), IlluminaInc. , GSK plc , HUTCHMED .
The market report covers data from the North America.
